CGRP vs Teduglutide

Binds CLR/RAMP1 receptor complex. Causes vasodilation via cAMP/PKA/nitric oxide pathway. Modulates nociceptive signaling in the trigeminal system. Promotes bone healing and has anti-inflammatory effects in peripheral tissues.

CGRP (calcitonin gene-related peptide) is a 37-amino-acid endogenous neuropeptide produced by alternative splicing of the calcitonin gene, expressed predominantly in sensory neurons of the trigeminal system and peripheral vasculature, where it functions as a potent vasodilator and pain neuromodulator central to migraine pathophysiology. CGRP activates its receptor complex (CLR/RAMP1) to mediate vasodilation and nociceptive signal amplification; during migraine attacks, trigeminal activation releases CGRP at elevated plasma concentrations, and blockade of this pathway has been established as the primary validated pharmacological target for modern preventive migraine therapy. Phase 3 randomized controlled trials published in the New England Journal of Medicine and the Lancet — including the STRIVE trial (Goadsby et al. 2017) and a Phase 3b study in treatment-refractory patients — demonstrated that anti-CGRP monoclonal antibodies significantly reduced monthly migraine days versus placebo, validating the pathway and supporting FDA approval of erenumab, fremanezumab, and galcanezumab. CGRP itself is an endogenous neuropeptide and is not a therapeutic agent that is compounded or administered by providers; the FDA-approved interventions are monoclonal antibody and small-molecule receptor antagonists available by prescription, and exogenous CGRP peptide is exclusively a research tool compound used in vasodilatory and pain signaling pharmacology studies.

GLP-2 receptor agonist; stimulates intestinal epithelial proliferation and reduces apoptosis; increases intestinal blood flow and inhibits gastric motility

Teduglutide (Gattex in the United States, Revestive in the European Union) is a GLP-2 analogue and FDA-approved prescription medication indicated for short bowel syndrome (SBS) with intestinal failure in adults and pediatric patients, designed to reduce dependence on parenteral nutrition and intravenous fluids by promoting intestinal mucosal growth and enhancing residual bowel absorptive capacity. By activating GLP-2 receptors on intestinal subepithelial myofibroblasts and enteric neurons, teduglutide stimulates paracrine release of insulin-like growth factor 1 (IGF-1) and keratinocyte growth factor (KGF), driving enterocyte crypt cell proliferation, increasing villus height, and expanding mucosal absorptive surface area to improve nutrient and fluid absorption from functionally compromised residual bowel. A systematic review and meta-analysis of Phase 3 registrational trial data published in the Journal of Parenteral and Enteral Nutrition documented significant reductions in parenteral nutrition volume requirements, and long-term follow-up data published in Clinical and Translational Gastroenterology confirmed durable reductions in parenteral support needs over extended treatment periods. Teduglutide is an FDA-approved prescription medication; it is indicated for adults and pediatric patients (≥1 year) with SBS dependent on parenteral support, and use outside this indication or without physician supervision is not supported by established safety and efficacy data.